A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors - Trial NCT06329206
Access comprehensive clinical trial information for NCT06329206 through Pure Global AI's free database. This Phase 1 trial is sponsored by Suzhou Genhouse Bio Co., Ltd. and is currently Recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 156 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Suzhou Genhouse Bio Co., Ltd.
Timeline & Enrollment
Phase 1
Mar 20, 2024
Sep 01, 2026
Primary Outcome
Safety assessment
Summary
This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety,
 tolerability, PK, pharmacodynamics (PD) and preliminary efficacy of GH2616 Tablet in subjects
 with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and
 the dose expansion study (Phase Ib).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06329206
Non-Device Trial